Company Encyclopedia
View More
name
Azitra
AZTR.US
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S.
1.902 T
AZTR.USMarket value -Rank by Market Cap -/-

Financial Score

15/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking386/395
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-215.04%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY-23.11%D
    • Total Assets YoY-56.02%E
    • Net Assets YoY-71.72%E
  • Cash ScoreE
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreC
    • Gearing Ratio47.00%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Azitra Inc Secures $1.5M in Private Placement

    Azitra Inc. announced a $1.5M private placement with an institutional investor on November 24, 2025. The offering includes common stock and warrants, with proceeds for general corporate purposes. Restrictions on issuing additional shares for 60 days and investor participation rights in future financings are included. Maxim Group LLC facilitated the placement. Azitra must file a registration statement for resale of securities. Analysts rate AZTR stock as a Sell with a $0.50 price target, citing high losses and negative cash flows despite revenue growth.

    Tip Ranks·
    US
    AZTR
    -12.94%
    Tip Ranks·
    US
    AZTR
    -12.94%

    Azitra Inc. Announces $1.5 Million Private Placement Financing

    Azitra Inc., a biopharmaceutical company, announced a $1.5 million private placement financing with an institutional investor. The deal includes 4,687,500 shares of common stock and warrants, priced at $0.32 each. The warrants, exercisable upon shareholder approval, expire in five years. Maxim Group LLC is the sole placement agent, with the closing expected around November 25, 2025. This information is for informational purposes only and not financial advice.

    Reuters·
    US
    AZTR
    -12.94%
    Reuters·
    US
    AZTR
    -12.94%

    Azitra | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    AZTR
    -12.94%
    LB filings·
    US
    AZTR
    -12.94%

    Azitra posts Q3 net loss of $2.8 million on $1.4 million cash balance

    Azitra Inc. reported a Q3 net loss of $2.8 million for the quarter ending September 30, 2025, compared to a $1.0 million loss in Q3 2024. R&D expenses increased to $1.2 million, while general and administrative expenses decreased to $1.6 million. The company held $1.4 million in cash as of September 30, 2025, and raised $2.8 million through an equity line of credit. Key developments included dosing the first patient in a Phase 1⁄2 trial for the ATR-04 program and presenting positive preclinical data for ATR-01.

    Reuters·
    US
    AZTR
    -12.94%
    Reuters·
    US
    AZTR
    -12.94%

    Azitra, Inc. Addresses False Report Regarding Sale Of Securities

    Nov 7 (Reuters) - Azitra Inc (AZTR.A) :* AZITRA, INC. ADDRESSES FALSE REPORT REGARDING SALE OF SECURITIES* AZITRA - REPORT CIRCULATED CLAIMING THAT CO PRICED A $44 MILLION REGISTERED DIRECT OFFERING IS FALSE AND SHOULD NOT BE RELIED UPON* AZITRA INC - TAKING STEPS TO IDENTIFY SOURCE OF FALSE REPORT Source text: Further company coverage: (AZTR.A)

    Reuters·
    US
    AZTR
    -12.94%
    Reuters·
    US
    AZTR
    -12.94%
    © 2025 Longbridge｜Disclaimer